Trials / Conditions / Stage IVA Salivary Gland Cancer

Stage IVA Salivary Gland Cancer

17 registered clinical trials studyying Stage IVA Salivary Gland Cancer.

Status	Trial	Sponsor	Phase
Completed	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	—
Completed	Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511	Mayo Clinic	Phase 2
Completed	PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984	University of Chicago	Phase 1 / Phase 2
Completed	18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675	Sanjiv Sam Gambhir	Phase 1 / Phase 2
Completed	Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer NCT01613768	University of Washington	Phase 2
Terminated	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137	Stanford University	Phase 1
Completed	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627	National Cancer Institute (NCI)	Phase 2
Completed	Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194	Fox Chase Cancer Center	Phase 1
Completed	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429	Ohio State University Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767	National Cancer Institute (NCI)	Phase 2
Terminated	Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer NCT00126607	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer NCT00114283	National Cancer Institute (NCI)	Phase 2
Completed	SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00095628	National Cancer Institute (NCI)	Phase 2
Completed	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512	National Cancer Institute (NCI)	Phase 2
Completed	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497	National Cancer Institute (NCI)	N/A
Completed	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck NCT00033618	National Cancer Institute (NCI)	Phase 2